Maximising the Commercial Value of your University Research - Avoiding IP Pitfalls: Selling reagents, understanding MTAs and 3rd party rights

Increasingly academic researchers find themselves signing MTAs to access reagents, providing reach through rights to 3rd parties and/or making use of research technologies (such as CRISPR) that are subject to active patent protection. Although this can accelerate research progress, it also provide significant baggage for your innovations, and may well impact on the potential for commercial development of your ideas.
This seminar will discuss the challenges faced, and aims to identify some smart strategies to plan for and avoid some of the pitfalls.